144 related articles for article (PubMed ID: 38176268)
21. Ginsenoside Rg2 Ameliorates High-Fat Diet-Induced Metabolic Disease through SIRT1.
Cheng B; Gao W; Wu X; Zheng M; Yu Y; Song C; Miao W; Yang Z; He Y; Liu C; Yang W; Yang X; Li Y; Zhang F; Gao Y
J Agric Food Chem; 2020 Apr; 68(14):4215-4226. PubMed ID: 32181656
[TBL] [Abstract][Full Text] [Related]
22. Nobiletin mitigates hepatocytes death, liver inflammation, and fibrosis in a murine model of NASH through modulating hepatic oxidative stress and mitochondrial dysfunction.
Li S; Li X; Chen F; Liu M; Ning L; Yan Y; Zhang S; Huang S; Tu C
J Nutr Biochem; 2022 Feb; 100():108888. PubMed ID: 34695558
[TBL] [Abstract][Full Text] [Related]
23. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
Wang Q; Zhou H; Bu Q; Wei S; Li L; Zhou J; Zhou S; Su W; Liu M; Liu Z; Wang M; Lu L
J Hepatol; 2022 Aug; 77(2):312-325. PubMed ID: 35292349
[TBL] [Abstract][Full Text] [Related]
24. SGL 121 Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism Through AMPK Signaling Pathway.
Kim DE; Chang BY; Jeon BM; Baek JI; Kim SC; Kim SY
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630596
[TBL] [Abstract][Full Text] [Related]
25. Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, inflammation and fibrosis in mice.
Zhang J; Zhang H; Deng X; Zhang N; Liu B; Xin S; Li G; Xu K
Life Sci; 2018 Jan; 192():46-54. PubMed ID: 29158052
[TBL] [Abstract][Full Text] [Related]
26. Ginsenoside Mc1 improves liver steatosis and insulin resistance by attenuating ER stress.
Roh E; Hwang HJ; Kim JW; Hong SH; Kim JA; Lee YB; Choi KM; Baik SH; Yoo HJ
J Ethnopharmacol; 2020 Sep; 259():112927. PubMed ID: 32387461
[TBL] [Abstract][Full Text] [Related]
27. Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder.
Hu J; Wang H; Li X; Liu Y; Mi Y; Kong H; Xi D; Yan W; Luo X; Ning Q; Wang X
Theranostics; 2020; 10(21):9702-9720. PubMed ID: 32863955
[No Abstract] [Full Text] [Related]
28. Kaempferol Alleviates Hepatic Injury in Nonalcoholic Steatohepatitis (NASH) by Suppressing Neutrophil-Mediated NLRP3-ASC/TMS1-Caspase 3 Signaling.
Yang H; Li D; Gao G
Molecules; 2024 Jun; 29(11):. PubMed ID: 38893506
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-122 Inhibits Lipid Droplet Formation and Hepatic Triglyceride Accumulation via Yin Yang 1.
Wu GY; Rui C; Chen JQ; Sho E; Zhan SS; Yuan XW; Ding YT
Cell Physiol Biochem; 2017; 44(4):1651-1664. PubMed ID: 29216638
[TBL] [Abstract][Full Text] [Related]
30. Fenofibrate alleviates NAFLD by enhancing the PPARα/PGC-1α signaling pathway coupling mitochondrial function.
Wang X; Wang J; Ying C; Xing Y; Su X; Men K
BMC Pharmacol Toxicol; 2024 Jan; 25(1):7. PubMed ID: 38173037
[TBL] [Abstract][Full Text] [Related]
31. Tyrosol attenuates NASH features by reprogramming the hepatic immune milieu.
Gabbia D; Sayaf K; Zanotto I; Colognesi M; Frion-Herrera Y; Carrara M; Russo FP; De Martin S
Eur J Pharmacol; 2024 Apr; 969():176453. PubMed ID: 38408597
[TBL] [Abstract][Full Text] [Related]
32. Blockade of C5aR1 alleviates liver inflammation and fibrosis in a mouse model of NASH by regulating TLR4 signaling and macrophage polarization.
Jiang K; Lu S; Li D; Liu M; Jin H; Lei B; Wang S; Long K; He S; Zhong F
J Gastroenterol; 2023 Sep; 58(9):894-907. PubMed ID: 37227481
[TBL] [Abstract][Full Text] [Related]
33. Ginsenoside Rg1 attenuates the NASH phenotype by regulating the miR-375-3p/ATG2B/PTEN-AKT axis to mediate autophagy and pyroptosis.
Chen X; Xue W; Zhang J; Peng J; Huang W
Lipids Health Dis; 2023 Feb; 22(1):22. PubMed ID: 36759837
[TBL] [Abstract][Full Text] [Related]
34. [Notch1 inhibits the mechanistic role of STING signaling to regulate hepatocyte lipophagy in nonalcoholic steatohepatitis].
Yang T; Zhao JY; Wang X; Fang ZG; Jiang LF; Li J
Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):827-834. PubMed ID: 37723064
[No Abstract] [Full Text] [Related]
35. Ginsenoside Rg5 attenuates hepatic glucagon response via suppression of succinate-associated HIF-1α induction in HFD-fed mice.
Xiao N; Lou MD; Lu YT; Yang LL; Liu Q; Liu B; Qi LW; Li P
Diabetologia; 2017 Jun; 60(6):1084-1093. PubMed ID: 28280902
[TBL] [Abstract][Full Text] [Related]
36. Polydatin attenuates diet-induced nonalcoholic steatohepatitis and fibrosis in mice.
Li R; Li J; Huang Y; Li H; Yan S; Lin J; Chen Y; Wu L; Liu B; Wang G; Lan T
Int J Biol Sci; 2018; 14(11):1411-1425. PubMed ID: 30262993
[No Abstract] [Full Text] [Related]
37. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
[TBL] [Abstract][Full Text] [Related]
38. Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity.
Yang M; Kimchi ET; Staveley-O'Carroll KF; Li G
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681695
[TBL] [Abstract][Full Text] [Related]
39. ARRB1 inhibits non-alcoholic steatohepatitis progression by promoting GDF15 maturation.
Zhang Z; Xu X; Tian W; Jiang R; Lu Y; Sun Q; Fu R; He Q; Wang J; Liu Y; Yu H; Sun B
J Hepatol; 2020 May; 72(5):976-989. PubMed ID: 31857195
[TBL] [Abstract][Full Text] [Related]
40. FTZ attenuates liver steatosis and fibrosis in the minipigs with type 2 diabetes by regulating the AMPK signaling pathway.
Wang H; Huang M; Bei W; Yang Y; Song L; Zhang D; Zhan W; Zhang Y; Chen X; Wang W; Wang L; Guo J
Biomed Pharmacother; 2021 Jun; 138():111532. PubMed ID: 34311531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
